Business Context and Reporting Period
This Form 8-K reports on the results of Immunovant, Inc.'s 2026 Annual Meeting of Stockholders held on September 2, 2026. The company is incorporated in Delaware and its common stock trades on The Nasdaq Stock Market under the symbol IMVT.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and stockholder voting outcomes.
Material Changes and Voting Results
Approximately 96% of entitled shares (198,373,370 shares) were represented at the meeting. Stockholders approved three proposals:
- Proposal 1 (Election of Directors): Jacob Bauer, Douglas Hughes, and Robert Susman were elected to the Board of Directors. Robert Susman received the highest support with 181,604,476 votes for, while Jacob Bauer received 162,872,114 votes for.
- Proposal 2 (Ratification of Auditors): Stockholders ratified the selection of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending March 31, 2027. The vote was 198,148,265 for versus 187,390 against.
- Proposal 3 (Executive Compensation): Stockholders approved the compensation of Named Executive Officers on a non-binding advisory basis. The vote was 180,772,822 for versus 8,437,839 against.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for financial guidance, future outlook, management commentary on operations, specific risks, contingencies, or unusual items. The document serves solely to disclose the voting results of the Annual Meeting.
Important Facts for Investors to Verify
- Verify the composition of the newly elected Board of Directors and their tenure until the 2027 Annual Meeting.
- Confirm the engagement of Ernst & Young LLP for the fiscal year ending March 31, 2027.
- Review the definitive Proxy Statement filed on July 22, 2026, for detailed narratives regarding executive compensation and director qualifications.
- Note the high level of stockholder participation (96%) and the significant margin of approval for all three proposals.